InterAx, a Swiss biotech spin-off of the ETH Zurich, developed a proprietary discovery platform to decipher and guide the optimization of intracellular pathways: one of the least understood “black boxes” in biology and a significant point of failure for new medicines. InterAx is guiding intracellular pathways optimization by combining experimental pharmacology, mathematical modeling, and artificial intelligence. It is setting an industry example of how to understand better and de-risk drug candidates: by leveraging not just large quantities of data with machine learning algorithms, but simultaneously incorporating crucial biological knowledge of the underlying system into the intelligent drug discovery algorithms. InterAx technology platform is already commercialized to three pharma and biotech companies Boehringer Ingelheim, Lundbeck, and GPCR Therapeutics. InterAx is also advancing it own program in oncology, currently in animal testing, which will be out-licensed.